


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of formula I



in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydrogen, hydroxy, or C1-C4-alkyl optionally substituted by hydroxy;

L and M are (a bond and $-CH_2-CH_2-$), $(-CH_2-$ and $-CH_2-CH_2-)$ or $(-CH_2-CH_2-$ and $-CH_2-)$ respectively and J is C1-C2-alkylene;

or L and M are $(-CH_2-$ and $-CH_2-CH_2-)$ or $(-CH_2-CH_2-$ and $-CH_2-)$ respectively and J is a bond;

R^4 is C1-C4-alkyl;

R^5 is C1-alkyl substituted by $-SO-R^6$, $-S(=O)_2-R^6$, $-CO-R^6$, $-CO-O-R^6$, or $-CO-NH-R^6$ or $-R^7$, or R^5 is C2-C10-alkyl substituted by $-O-R^6$, $-S-R^6$, $-SO-R^6$, $-S(=O)_2-R^6$, $-CO-R^6$, $-O-CO-R^6$, $-CO-O-R^6$, $-NH-CO-R^6$, $-CO-NH-R^6$, $-R^7$ or $-R^8$,

or R^5 is C2-C10-alkenyl or C2-C10-alkynyl optionally substituted by $-R^7$ or $-R^8$;

R^6 is a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur,

or R^6 is C1-C10-alkyl optionally substituted by C1-C10-alkoxy, $-O-R^7$, $-O-R^8$ a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur; and

R^7 is a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur; and

R^8 is a C3-C15-carbocyclic group.

Claim 2. (Currently Amended) A compound according to claim 1, wherein

R^1 and R^3 are each independently a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydroxy;

L and M are (a bond and $-CH_2-CH_2-$), $(-CH_2-$ and $-CH_2-CH_2-)$ or $(-CH_2-CH_2-$ and $-CH_2-)$ respectively and J is C1-C2-alkylene;


or L and M are ~~(-CH₂- and -CH₂-CH₂-)~~ or ~~(-CH₂-CH₂- and -CH₂-)~~ respectively and J is a bond;
R⁴ is C₁-C₄-alkyl;
R⁵ is C₁-alkyl substituted by -CO-R⁶ or -CO-NH-R⁶,
or R⁵ is C₂-C₁₀-alkyl substituted by -O-R⁶, -S-R⁶, -O-CO-R⁶ or -R⁸,
or R⁵ is C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl optionally substituted by -R⁸;
R⁶ is a C₃-C₁₅-carbocyclic group,
or R⁶ is C₁-C₁₀-alkyl optionally substituted by C₁-C₁₀-alkoxy, O-R⁸ or a C₃-C₁₅-carbocyclic group; and
R⁸ is a C₃-C₁₅-carbocyclic group.

Claim 3. (Currently Amended) A compound according to claim 2, wherein
R¹ and R³ are each independently a C₃-C₁₀-carbocyclic group, preferably phenyl, or a 5- to 9-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur, preferably thienyl;
R² is hydroxy;

~~L and M are (a bond and -CH₂-CH₂-), (-CH₂- and -CH₂-CH₂-) or (-CH₂-CH₂- and -CH₂-) respectively and J is C₁-C₂-alkylene;~~
~~or L and M are (-CH₂- and -CH₂-CH₂-) or (-CH₂-CH₂- and -CH₂-) respectively and J is a bond;~~
R⁴ is C₁-C₄-alkyl;
R⁵ is C₁-alkyl substituted by -CO-R⁶ or -CO-NH-R⁶,
or R⁵ is C₂-C₅-alkyl substituted by -O-R⁶, -S-R⁶, -O-CO-R⁶ or -R⁸,
or R⁵ is C₂-C₄-alkenyl or C₂-C₈-alkynyl optionally substituted by -R⁸;
R⁶ is a C₃-C₁₀-carbocyclic group, preferably phenyl,
or R⁶ is C₁-C₁₅-alkyl optionally substituted by C₁-C₄-alkoxy, O-R⁸ or a C₃-C₁₀-carbocyclic group; and
R⁸ is a C₃-C₁₀-carbocyclic group, preferably phenyl.









Claims 4-7. (Canceled)


Claim 8. (Currently Amended): A compound according to claim 1, which is also a compound of formula XVI





where T is as shown in the following table:


T
















Claim 9. (Currently Amended): A compound according to claim 1, which is also a compound of formula XVII





XVII


where T is as shown in the following table:


T












Claim 10. (Cancelled)

Claim 11. (Previously Presented): A pharmaceutical composition comprising as active ingredient a compound according to claim 1.

Claims 12-15. (Cancelled)

Claim 16. (Currently Amended): A process for the preparation of a compound of formula I as claimed in claim 1 which comprises:

(i) (A) reacting a compound of formula II




or a protected form thereof where R^1 , R^2 , R^3 , R^4 , and J, — are as defined in claim 1, with a compound of formula III



where R^5 is as defined in claim 1 and X is chloro, bromo or iodo;

(B) reacting a compound of formula IV




or a protected form thereof where R^1 , R^2 , R^3 , R^5 , J, L and M are as defined in claim 1, with a compound of formula V




where R^4 is as defined in claim 1 and X is chloro, bromo or iodo;

(C) for the preparation of compounds of formula I where R^5 is $-Q-NH-CO-R^6$, reacting a compound of formula VI




or a protected form thereof where R^1, R^2, R^3, R^4, J, L and M are as defined in claim 1 and Q is C_1 - C_{10} -alkylene, with a compound of formula VII



or an amide-forming derivative thereof wherein R^6 is as defined in claim 1; or
(D) for the preparation of compounds of formula I where R^5 is C_1 - C_{10} -alkyl substituted by a C_3 - C_{15} -carbocyclic group that is substituted by carboxy, converting a compound of formula I where R^1, R^2, R^3, R^4, J, L and M are as defined in claim 1 and R^6 is C_1 - C_{10} -alkyl substituted by a C_3 - C_{15} -carbocyclic group that is substituted by either $-\text{COO}-C_6$ - C_{10} -aryl or $-\text{COO}-C_7$ - C_{15} -aralkyl; and

(ii) recovering the product in salt or zwitterionic form.

Claim 17. (Currently Amended): A compound of formula VI



in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C_3 - C_{15} -carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydrogen, hydroxy, or C_1 - C_4 -alkyl optionally substituted by hydroxy;

L and M are (a bond and $-\text{CH}_2-\text{CH}_2-$), ($-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-$) or ($-\text{CH}_2-\text{CH}_2-$ and $-\text{CH}_2-$) respectively and J is C_1 - C_2 -alkylene;

or L and M are ($-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-$) or ($-\text{CH}_2-\text{CH}_2-$ and $-\text{CH}_2-$) respectively and J is a bond;

R^4 is C_1 - C_4 -alkyl; and

Q is C_1 - C_{10} -alkylene.

Claim 18. (Original): A pharmaceutical composition according to claim 11 wherein the compound is a single enantiomer.

Claim 19. (Cancelled)

Claim 20. (Withdrawn - Original): A method of treating a condition mediated by the muscarinic M3 receptor in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 21. (Withdrawn - Original): A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject

an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 22. (Withdrawn - Original): A method according to claim 20, in which the compound of formula I is a single enantiomer.